search
Back to results

Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study

Primary Purpose

Heart Disease

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
EPA-DHA Study
Sponsored by
Cardiovascular Research Associates
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Heart Disease

Eligibility Criteria

21 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy male or surgically sterile females between ages 21-70.
  • Body Mass Index of 20-35.
  • Plasma Lipoprotein Associated Phospholipase A2 (LpPLA2) values > 200 ng/ml.

Exclusion Criteria:

  • Competitive exerciser.
  • Current smoker.
  • Those already taking dietary supplements (EPA, DHA, flax seed oil, fish oil, cod liver oil, weight control products, or high doses of vitamin C (>500 mg/day) or vitamin E (>400 mg/day).
  • Those consuming more than 3 oily fish species/week.
  • Those consuming >2 drinks containing alcohol/day.
  • Those taking medications which could affect serum lipids or body weight, or taking coumadin or more than 325 mg/day of aspirin which could effect bleeding time or the coagulation profile.
  • History of a bleeding disorder.
  • History of significant cardiac, renal, hepatic, gastro-intestinal, pulmonary, neoplastic, biliary or endocrine disorders including uncontrolled diabetes, thyroid disease, or hypertension.
  • Plasma LpPLA2 values < 200 ng/ml.

Sites / Locations

  • Cardiovascular Research Associates

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Olive Oil 6 grams/day

DHA 1800 mg/day

EPA 1800 mg/day

Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day

Arm Description

Outcomes

Primary Outcome Measures

plasma EPA levels as well as the EPA/DHA ratio and plasma DHA levels as well as the DHA/EPA ratio
Subjects receiving EPA at 1800 mg/day will have significantly greater plasma EPA levels as well as the EPA/DHA ratio than the placebo group or the group receiving DHA, while the group receiving DHA will have significantly greater increases in plasma DHA levels as well as the DHA/EPA ratio than the placebo group or the group receiving EPA.

Secondary Outcome Measures

LpPLA2
Subjects receiving the active supplement, especially at the 1800 mg daily dose of EPA will have significant reductions in LpPLA2 as compared to both baseline values and to the placebo group.

Full Information

First Posted
July 21, 2011
Last Updated
July 21, 2011
Sponsor
Cardiovascular Research Associates
Collaborators
Dupont Applied Biosciences
search

1. Study Identification

Unique Protocol Identification Number
NCT01400490
Brief Title
Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study
Official Title
Evaluation of the Biologic Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)-Enriched Oils (EPA-DHA Study)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2011
Overall Recruitment Status
Unknown status
Study Start Date
September 2010 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
September 2011 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Cardiovascular Research Associates
Collaborators
Dupont Applied Biosciences

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of the study is to test the efficacy of an EPA-enriched oil made by DuPont versus a DHA-enriched oil, a standard fish oil preparation, and olive oil placebo in a double-blind, randomized, placebo-controlled trial. This study will compare the efficacy of 1800 mg/day of EPA versus 1800 mg/day of DHA versus a fish oil product containing 1800 mg of EPA and 1200 mg of DHA/day as compared to olive oil placebo at 6 grams/day over a 6 week period in a parallel arm design study of 120 healthy adults studied in both the fasting and post-prandial state. Safety will be monitored by assessing for adverse reactions, measuring vital signs and a variety of lab tests including a complete metabolic profile and complete blood count. Efficacy will be assessed by measuring changes in fatty acid profile and or fatty acid ratios,as well as by measuring plasma lipids, lipoproteins, and markers of inflammation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Disease

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Olive Oil 6 grams/day
Arm Type
Placebo Comparator
Arm Title
DHA 1800 mg/day
Arm Type
Active Comparator
Arm Title
EPA 1800 mg/day
Arm Type
Active Comparator
Arm Title
Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day
Arm Type
Active Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
EPA-DHA Study
Intervention Description
6 weeks of dietary supplementation
Primary Outcome Measure Information:
Title
plasma EPA levels as well as the EPA/DHA ratio and plasma DHA levels as well as the DHA/EPA ratio
Description
Subjects receiving EPA at 1800 mg/day will have significantly greater plasma EPA levels as well as the EPA/DHA ratio than the placebo group or the group receiving DHA, while the group receiving DHA will have significantly greater increases in plasma DHA levels as well as the DHA/EPA ratio than the placebo group or the group receiving EPA.
Time Frame
Six weeks
Secondary Outcome Measure Information:
Title
LpPLA2
Description
Subjects receiving the active supplement, especially at the 1800 mg daily dose of EPA will have significant reductions in LpPLA2 as compared to both baseline values and to the placebo group.
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy male or surgically sterile females between ages 21-70. Body Mass Index of 20-35. Plasma Lipoprotein Associated Phospholipase A2 (LpPLA2) values > 200 ng/ml. Exclusion Criteria: Competitive exerciser. Current smoker. Those already taking dietary supplements (EPA, DHA, flax seed oil, fish oil, cod liver oil, weight control products, or high doses of vitamin C (>500 mg/day) or vitamin E (>400 mg/day). Those consuming more than 3 oily fish species/week. Those consuming >2 drinks containing alcohol/day. Those taking medications which could affect serum lipids or body weight, or taking coumadin or more than 325 mg/day of aspirin which could effect bleeding time or the coagulation profile. History of a bleeding disorder. History of significant cardiac, renal, hepatic, gastro-intestinal, pulmonary, neoplastic, biliary or endocrine disorders including uncontrolled diabetes, thyroid disease, or hypertension. Plasma LpPLA2 values < 200 ng/ml.
Facility Information:
Facility Name
Cardiovascular Research Associates
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02112
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
26074314
Citation
Tsunoda F, Lamon-Fava S, Asztalos BF, Iyer LK, Richardson K, Schaefer EJ. Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression. Atherosclerosis. 2015 Aug;241(2):400-8. doi: 10.1016/j.atherosclerosis.2015.05.015. Epub 2015 May 19.
Results Reference
derived

Learn more about this trial

Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study

We'll reach out to this number within 24 hrs